Is Durysta Approved by the FDA? A Comprehensive Pharmacology Overview
•
4 min read
Approved by the U.S. Food and Drug Administration (FDA) on March 4, 2020, Durysta (bimatoprost implant) is a significant advancement in glaucoma therapy. This intracameral, biodegradable, sustained-release implant provides a continuous, drop-free method for reducing high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
